A record of what Axis Securities Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Maintains a bullish view on the pharmaceuticals industry, which appears well-positioned for FY26 and beyond. This is supported by a strong product pipeline in biosimilars, GLP-1, and peptides, with chronic therapies outperforming the overall Indian Pharmaceutical Market. Margins are expected to remain stable to improving, aided by a favorable product mix and easing input costs.”
Axis Securities Analysis’s track record (trackable calls only): 155 graded calls · 95% CI 34–49%
Nifty PharmaBullishCalled 05 Jun 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Axis Securities Analysis’s full track record